Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

5AM Ventures

Investor type Venture Capital
Founders Andrew Schwab John Diekman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 170
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 79
Rounds per year 8.50
Lead investments 38
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.53
Exits 36
Key employees 8
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

5AM Ventures appeared to be the VC, which was created in 2002. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Menlo Park.

The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Ikaria, Relypsa We can highlight the next thriving fund investment areas, such as Life Science, Therapeutics.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the 5AM Ventures, startups are often financed by Clarus Ventures, ARCH Venture Partners, Sprout Group. The meaningful sponsors for the fund in investment in the same round are Roche Venture Fund, Frazier Healthcare Partners, Clarus Ventures. In the next rounds fund is usually obtained by ARCH Venture Partners, Roche Venture Fund, Aravis Ventures.

The current fund was established by Andrew Schwab, John Diekman. Besides them, we counted 8 critical employees of this fund in our database.

The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 12 percentage points more often commits exit comparing to other companies. When the investment is from 5AM Ventures the average startup value is 10-50 millions dollars. Opposing the other organizations, this 5AM Ventures works on 8 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2018. The fund is constantly included in 7-12 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 5AM Ventures:
Typical Co-investors
5AM Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 5AM Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Novome Biotechnologies

Biopharma
Biotechnology
Therapeutics
$43M13 Sep 2022 South San Francisco, California, United States

Disc Medicine

Biotechnology
Health Care
Medical
$53M10 Aug 2022 Cambridge, Massachusetts, United States

CAMP4 Therapeutics

Biopharma
Biotechnology
Therapeutics
$100M20 Jul 2022 Cambridge, Massachusetts, United States

Magnetic Insight

Health Care
Life Science
Medical Device
$17M23 Jun 2022 California, United States

Dianthus Therapeutics

Biopharma
Biotechnology
Health Care
$100M19 Apr 2022 Waltham, Massachusetts, United States

GlycoEra

Biotechnology
$49M05 Nov 2021 Schlieren, Zurich, Switzerland

Radionetics Oncology

Pharmaceutical
Therapeutics
$30M18 Oct 2021 California City, California, United States

Expansion Therapeutics

Biotechnology
Health Care
Therapeutics
$80M29 Sep 2021 San Diego, California, United States

RareCyte

Biotechnology
Health Care
Health Diagnostics
Medical Device
$24M09 Sep 2021 Seattle, Washington, United States
News
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

TMRW Life Sciences Raises $105M in Funding

– TMRW Life Sciences, Inc., a NYC-based life sciences technology company providing an automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), completed a $105m Series C equity and debt financing.
– The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others.
– The company intends to use the funds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 5AM Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: